Press Enter to search · Esc to close
A synthesis of 16 systematic reviews puts hard numbers on a soft truth: the cleanest longevity move you can make for your vision is still to quit.
A provocative review of brain tissue from young Mexico City residents argues that ultrafine air pollution may seed neurodegeneration decades before symptoms appear. The evidence is moderate — but hard to unsee.
A quiet genetic shift called CHIP is turning up more often as we age — and researchers are connecting it to heart and blood disease. Here's what the evidence actually says.
A 2025 review reframes sarcopenia as a modifiable condition — and grades which interventions actually move the needle on muscle mass, fiber loss, and motor unit decline.
A new Physiology review maps how sympathetic nerves, baroreflexes and blood pressure shift across the menstrual cycle, pregnancy and menopause — and where the science still goes dark.
A new legal analysis warns that the same patent playbook that kept inhalers expensive for decades is now being run on GLP-1 drugs — just as millions of women are lining up for them.
A new perspective in Aging Cell argues that the body's capacity to buffer immune decline — not the disease markers we obsess over — may be the truer measure of how well we age.
The blockbuster weight-loss drug is being studied for far more than the scale. Here's what the newest research actually shows — and where the evidence still thins out.
A careful re-analysis of the Women's Health Initiative finds metformin initiators outlived sulfonylurea initiators on the way to age 90. It sharpens the longevity debate without ending it.
Pooled real-world data on oral semaglutide, a fresh meta-analysis on combining GLP-1s with SGLT2 inhibitors, and dietitians' candid notes on what makes these protocols stick.